

RESEARCH OPPORTUNITY

NAMI is committed to ensuring that the most effective treatments for mental illness are available to those who need them. Determining which treatments are most effective requires research. When NAMI is approached to be involved in research of any type, at any level, we take it very seriously. NAMI's Chief Medical Officer Dr. Ken Duckworth and Chief Program Officer Dr. Teri Brister thoroughly review the research protocols and methodology and the documentation that the study has been approved by an Institutional Review Board (IRB) to assure the safety of those involved.

NAMI does not accept financial compensation for recruiting clinical trial participants. NAMI also does not endorse any products or treatments. We share these research opportunity notices with you, our field leaders, to distribute at your discretion if you believe that members of your community may be interested in participating in these trials.

If you have questions about research at NAMI, please visit [NAMI.org/research](https://www.nami.org/research) or email us at research@nami.org.

WHAT IS THE STUDY?

This study is called EMERGENT-5 and is a clinical research trial for the investigational product KarXT (combination xanomeline-trospium). The trial will determine if KarXT is safe and effective in treating symptoms of schizophrenia in adults. Participants will be asked to discontinue use of any other medication to treat schizophrenia and take KarXT for 52 weeks; researchers will conduct safety and symptom assessments throughout the trial period and 1 week after study completion. Participants will receive payment for completed study visits and for completion of digital biomarker assessment surveys.

WHO CAN PARTICIPATE?

This study is seeking 600 participants. Participants may be eligible for this study if they are:

- Between the ages of 18 and 65
- Have a primary diagnosis of schizophrenia and stable symptoms
- Are willing to discontinue their anti-psychotic medication if they are already taking one

Please note that these criteria are not complete. Certain other factors may disqualify an individual from participation. For a full list of inclusion and exclusion criteria, please visit the [clinicaltrials.gov](https://www.clinicaltrials.gov) [trial website](https://www.clinicaltrials.gov/ct2/show/NCT04820309) (<https://www.clinicaltrials.gov/ct2/show/NCT04820309>) or visit the study [website](https://emergent-5.researchstudytrial.com/) (<https://emergent-5.researchstudytrial.com/>).

WHERE IS THE STUDY TAKING PLACE?

The study will take place at approximately 60 trial centers in the United States. All the study locations can be found at the [clinicaltrials.gov](https://www.clinicaltrials.gov) [site](https://www.clinicaltrials.gov) (scroll down to the "contacts and locations" section).

HOW DO I LEARN MORE?

If you have questions or would like more information, please refer to the [EMERGENT-5](https://www.emergent-5.com) website. Other inquiries for Karuna can be sent as an email to medinfo@karunatx.com.